Noninvasive preimplantation genetic testing for aneuploidy exhibits high rates of deoxyribonucleic acid amplification failure and poor correlation with results obtained using trophectoderm biopsy

Noninvasive preimplantation genetic testing for aneuploidy: Is the glass half-empty or half-full?

“…This possibility requires special precautions during embryo culture and media collection, particularly with extra care taken after denudation. Such steps are not described by Hanson et al (2); thus, it is unclear whether cumulus cell contamination was minimized. Other important factors that require adaptation for embryo cfDNA analysis are the whole-genome amplification protocols as well as the diagnostic rules and algorithms applied to analyse results.…”

“…However, an important limitation is that, although using a specific noninvasive PGT-A commercial kit, the study did not use embryologic and/or technical conditions modified from those used in invasive PGT-A. In particular, modification in the volume of the culture drop is necessary to concentrate embryo cfDNA and improve amplification rates; typically, drops should be 5-10 mL (1, 3) rather than the 30 mL used in this study (2). Reducing the volume of the culture drop does not impair blastocyst rates (4).…”

“…However, the ultimate goal would be to predict which medium corresponds to a blastocyst that can result in a healthy baby. In t Hanson et al study (2), clinical outcomes were assessed after transfer of embryos with euploid trophectoderm biopsies and concordant or discordant results in the medium. The limited number of embryos undergoing transfer with informative results for both sample types makes it difficult to draw definitive conclusions.…”

Character of cell-free genomic DNA in embryo culture medium and the prospect of its clinical application in preimplantation genetic testing

“…The basic composition of any media is water, salts, bicarbonate, glucose, pyruvate, amino acids, vitamins, and added with proteins. Since the first study analyzing mtDNA in the culture medium, different commercial media have been reported in cfDNA studies, for instance, Sydney IVF Blastocyst medium from Cook Medical [14,15] , G-series medium from Vitrolife [18,19,26,32,[44][45][46] , CCM medium from Vitrolife [33] , Quinn's Advantage Protein Plus blastocyst medium from SAGE [20,23] , Continuous single culture medium from Irvine Scientific [21,23,29] , Sage 1-Step medium from Origio [47] , and Origio Sequential Blast media from Cooper Surgical (Table 1) [48] . All these media were successfully amplified, indicating that the components in the media had a low influence on the success rate of amplification.…”

Website advertising of IVF add‐ons: Does PGT‐A live up to its billing?

“…However, studies involving niPGT-A have produced inconsistent results with recent reports pointing to very poor performance in the real-life clinical setting. 21 Remarkably, although still experimental, Lensen et al found two clinics advertising niPGT-A as a clinical treatment option with both claiming it to be beneficial. 1 According to recent Australian media reports, patients may have already lost embryos that were misdiagnosed as abnormal through niPGT-A in these clinics.…”